# ATYR catalysts: aTYR PHARMA INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/atyr/catalysts

> aTYR PHARMA INC (ATYR) has 1 upcoming catalyst. The next is the efzofitimod topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ATYR?

aTYR PHARMA INC (ATYR) has 1 upcoming catalyst. The next is the efzofitimod topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Topline results are expected in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/atyr/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001339970-26-000051, https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-08-07. Cite: https://sec-api.dev/companies/atyr/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | aTYR PHARMA INC |
| Ticker | ATYR (Nasdaq) |
| SEC CIK | 1339970 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/atyr |

## Cash runway

Cash $48.8M as of 2026-09-30; quarterly burn $9.5M; about 15.4 months of runway at that rate (XBRL company facts, accession 0001339970-26-000081).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2022 | [Efzofitimod trial start](https://sec-api.dev/pdufa/efzofitimod) | ATYR |  | completed | "In September 2022, we dosed the first patient in the study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1339970/000133997025000009/atyr-20250630.htm)) |
| Feb 2023 | [Efzofitimod trial start](https://sec-api.dev/pdufa/efzofitimod) | ATYR |  | completed | "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000083/atm_prosupp_nov_2026.htm)) |
| Oct 2023 | [Efzofitimod trial start](https://sec-api.dev/pdufa/efzofitimod) | ATYR |  | completed | "The study was initiated in the third quarter of 2023, and in October 2023, we dosed the first patient in this study." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1339970/000095017024139642/atm_prosupp_dec_2024.htm)) |
| Q2 2025 | [Efzofitimod interim data readout](https://sec-api.dev/pdufa/efzofitimod) | ATYR |  | scheduled | "Interim data from the study are expected in the second quarter of 2025 and will focus on skin assessments measured at baseline and week 12 in approximately eight patients, including patients in both the efzofitimod and placebo arms." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-ex99_1.htm)) |
| May 7, 2025 | [ATYR PHARMA INC earnings report](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed | "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-ex99_1.htm)) |
| June 25, 2025 | [Efzofitimod primary completion](https://sec-api.dev/pdufa/efzofitimod) | ATYR | Pulmonary Sarcoidosis | completed | "NCT05415137 (Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-25 (ACTUAL); Lead Sponsor aTyr Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05415137)) |
| Q3 2025 | [Efzofitimod topline data readout](https://sec-api.dev/pdufa/efzofitimod) | ATYR | pulmonary sarcoidosis | scheduled | "Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-ex99_1.htm)) |
| Sep 2025 | [ATYR PHARMA INC topline data readout](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed, missed | "In addition, in September 2025, we announced top-line results from the EFZO-FIT study, including that the study did not meet its primary endpoint." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm)) |
| Sep 2025 | [ATYR PHARMA INC topline data readout](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | scheduled | "Topline data from the study are expected in mid-September 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1339970/000133997025000009/atyr-20250630.htm)) |
| November 6, 2025 | [ATYR PHARMA INC earnings report](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed | "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000119312525269486/atyr-ex99_1.htm)) |
| April 2026 | [Efzofitimod primary completion](https://sec-api.dev/pdufa/efzofitimod) | ATYR | Interstitial Lung Disease | delayed | "NCT05892614 (Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-04 (ESTIMATED); Lead Sponsor aTyr Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05892614)) |
| May 15, 2026 | [ATYR PHARMA INC earnings report](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed | "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm)) |
| August 7, 2026 | [Efzofitimod earnings report](https://sec-api.dev/pdufa/efzofitimod) | ATYR |  | completed | "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm)) |
| November 5, 2026 | [ATYR PHARMA INC earnings report](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed | "Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000076/atyr-ex99_1.htm)) |
| Q1 2027 | [Efzofitimod topline data readout](https://sec-api.dev/pdufa/efzofitimod) | ATYR |  | scheduled | "Topline results are expected in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm)) |

## Drugs

- [Efzofitimod](https://sec-api.dev/pdufa/efzofitimod): pulmonary sarcoidosis, Interstitial Lung Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/atyr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ATYR catalysts: aTYR PHARMA INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/atyr/catalysts

```bibtex
@misc{secapidev_companies_atyr_catalysts_20261116,
  title        = {ATYR catalysts: aTYR PHARMA INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/atyr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_atyr_catalysts_20261116","title":"ATYR catalysts: aTYR PHARMA INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/atyr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
